Written by Jay Campbell
[Disclaimer: This article is for educational purposes only. Always consult with a qualified healthcare provider before starting any peptide protocol.]
Most peptide enthusiasts are flying blind with how they dose the ARA-290 peptide, copying protocols from underground forums and trusting dosage recommendations that have zero clinical validation.
But we already have legitimate human trial data on this compound, and the dosing sweet spot is far more defined than most people realize.
By this, I AM referring to phase II human trials with clear dosing protocols, safety data, and measurable outcomes.
This isn’t another peptide where we’re guessing based on animal models.
If you’ve read my guide on peptides for pain relief, you already know I’m bullish on ARA-290 for neuropathic conditions.
I’ve watched this peptide gain traction in optimization circles over the past few years, and I’ve seen both exceptional results and complete failures.
The latter are almost always traceable to dosing errors, unrealistic expectations, and/or fundamental misunderstandings about what ARA-290 actually does.
I AM going to solve this three problems by hooking you up with my ARA-290 peptide dosage chart.
While showing you exactly how to dose it based on what the science shows us.
Quick Takeaways
- Clinical trials consistently used 4 mg daily subcutaneously as the optimal therapeutic dose
- Higher doses (8 mg) show no additional benefit over 4 mg in neuropathy trials
- ARA-290 activates tissue repair pathways without stimulating red blood cell production
- Human safety data exists for protocols up to 28 days of daily use, and 15 weeks with tapered schedules
How ARA-290 Works: Mechanism of Action
ARA-290 is a peptide spanning 11 amino acids in length that selectively activates the innate repair receptor (IRR), a heterodimer complex of the erythropoietin receptor (EPOR) and β-common receptor (CD131).
Unlike erythropoietin (EPO), which drives red blood cell production and comes with cardiovascular risks, ARA-290 activates tissue repair signaling WITHOUT triggering erythropoiesis.
This small detail matters because it explains why this peptide works for neuroprotection and inflammation without the dangers of EPO.
When ARA-290 binds to IRR, it triggers downstream PI3K/Akt signaling, which leads to:
- Promoting cell survival
- Increasing anti-apoptotic proteins like Bcl-2
- Reducing pro-apoptotic proteins like Bax.
In other words, damaged cells get a survival signal instead of dying off.
Simultaneously, ARA-290 suppresses pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, while enhancing anti-inflammatory IL-10.
What you end up getting is inflammation modulation, which is NOT the same thing as immunosuppression — an important technicality to keep in mind if you’re concerned about infection risk.
For those of you who follow my work on NF-κB modulation through peptides like KPV, ARA-290 approaches inflammation from a complementary angle through the innate repair receptor pathway.
It also antagonizes the TRPV1 channel in small nerve fibers, which is a key integrator of pain signaling and neurogenic inflammation.
For these reasons, ARA-290 is being investigated for the treatment of neuropathic pain conditions.
ARA-290 Clinical Dosing: What Human Trials Reveal
The most robust human trial data for ARA-290 comes from phase II studies in patients with diabetic neuropathy and sarcoidosis-associated small-fiber neuropathy.
In the type 2 diabetes trial, researchers injected 4 mg of ARA-290 subcutaneously daily for 28 days and saw significant improvements in neuropathic symptoms and metabolic control that persisted one month after treatment stopped.
No clinically significant adverse effects were reported at this dose.
A separate double-blind, randomized trial for sarcoidosis-associated neuropathy tested doses ranging from 2–4 mg daily subcutaneously, showing both safety and preliminary efficacy in reducing pain and improving corneal nerve fiber density.
Most importantly, clinical trials tested doses ranging from 1–8 mg daily, and 4 mg per day emerged as the target therapeutic dose of ARA-290 (with no additional benefits observed at 8 mg).
This dose-response ceiling matters because more does NOT mean you’ll get better results with this peptide.
Another trial used a tapered protocol: 0.03 mg/kg subcutaneously every 2 days initially, then weekly for weeks 3–15, demonstrating tolerability over a 15-week period.
(NOTE: For a 200-pound (91 kg) individual, 0.03 mg/kg equals ~2.7 mg per dose)
ARA-290 Peptide Dosage Chart and Protocol Guide
Based on clinical trial data, here are the validated ARA-290 protocols.
| Protocol | Dose | Frequency | Route | Duration | Evidence Base |
| Standard Neuropathy | 4 mg | Daily | Subcutaneous | 28 days | Phase II diabetic neuropathy trial; strongest evidence base |
| Conservative | 2 mg | Daily | Subcutaneous | 28 days | Sarcoidosis trial lower range; reasonable starting point |
| Extended Tapered | ~0.03 mg/kg (~2.7 mg for 200 lb) | Every 2 days (weeks 1–2), then weekly (weeks 3–15) | Subcutaneous | 15 weeks | Longest validated protocol available |
| High-End (Not Recommended) | 8 mg | Daily | Subcutaneous | 28 days | Tested in trials; no superiority over 4 mg |
The pharmacokinetic data support the use of a daily dosing protocol.
ARA-290 exhibits high bioavailability (>85%) via subcutaneous injection but has a serum half-life measured in minutes, with metabolism primarily in the liver.
This short half-life means the compound clears quickly, making once-daily dosing logical for sustained receptor activation.
For guidance on reconstituting and injecting subcutaneous peptides correctly: See my Peptide Reconstitution: Dosing, Mixing and Storage Guide.
ARA-290 Peptide Stack: Best Combinations
As amazing as ARA-290 may appear in clinical trials, this peptide isn’t a standalone solution.
It’s a precision tool for a specific problem: Neuropathic pain and nerve fiber damage.
If you’re dealing with neuropathy, whether from diabetes, sarcoidosis, or other inflammatory conditions, ARA-290 is one of the most promising investigational compounds available.
But it works BEST when it is used as part of a comprehensive approach.
In my guide to peptides for pain relief, I position ARA-290 alongside BPC-157 and TB-500 for tissue repair, and KPV for upstream NF-κB modulation.
The logic is straightforward:
- BPC-157 repairs structural damage
- TB-500 accelerates cell migration and vessel formation
- KPV resolves inflammatory dysfunction
- ARA-290 activates the innate repair receptor for nerve-specific protection and pain reduction
Each peptide targets a different node in the pain and repair cascade.
ARA-290 is also listed in both our free-to-d0wnload guides, Peptide Cheat Sheet and Women’s Peptide Cheat Sheet, at 1–4 mg daily for 28-day cycles.
ARA-290 Uses Without Clinical Support
I keep seeing ARA-290 marketed for metabolic optimization, insulin sensitivity enhancement, stem cell proliferation, and wound healing.
Sadly, the evidence for these applications is primarily preclinical or speculative.
Animal studies show promise, including amelioration of chronic stress-induced depression-like behavior in mice through anti-inflammatory effects.
And the compound has legitimate mechanistic potential for neuroprotection based on its ability to reduce neuroinflammation, improve mitochondrial function, and enhance nerve fiber survival in neuropathy models.
But extrapolating mouse data to human optimization protocols requires intellectual honesty about the gaps.
Furthermore, if you’re using this for general “metabolic enhancement” or as a catch-all anti-aging peptide, you’re operating on blind hope.
What this means for you: Use ARA-290 for neuropathic pain and nerve repair only.
For metabolic optimization, you have far better tools available through modalities such as hormone optimization, agents like Metformin, and other peptides like MOTS-C that have stronger mechanistic and experiential data for those specific applications.
ARA-290 Side Effects and Safety Profile
No clinically significant adverse effects were reported at 4 mg daily subcutaneous ARA-290 in the 28-day human trials.
The most common side effects are transient injection-site reactions: swelling, redness, and mild pain… nothing you wouldn’t expect from any subcutaneous peptide injection.
Unfortunately, the total number of patients treated in published ARA-290 trials is approximately 100 across all the available studies.
We’re missing large Phase III trials, meta-analyses, or long-term safety data beyond 15 weeks.
Does this small sample size necessarily mean ARA-290 is dangerous?
Absolutely not.
It means we’re early, just like we were early with SS-31, MOTS-C, and virtually every other therapeutic peptide years before mainstream medicine ever caught up.
I’ve been experimenting with compounds that have limited human data for over three decades.
The absence of large-scale trials is not the same as the absence of safety evidence.
The mechanism for ARA-290 is clean, its Phase II data is clean, and the peptide was specifically engineered to avoid the cardiovascular risks of EPO.
That said, given the peptide’s structural relationship to EPO and its activation of EPOR (even in a tissue-repair context), monitoring your bloodwork during use is non-negotiable.
I’ve been getting comprehensive blood labs every 12 weeks for over three decades, and I STILL do it without exception.
ARA-290 Protocol: Real-World Application
If I were designing a protocol for someone with confirmed small-fiber neuropathy or chronic neuropathic pain unresponsive to other interventions, I’d start with the already-validated 4 mg daily administered via subcutaneous injection for 28 days.
Reassess symptoms and measure the relevant biomarkers of inflammation (hsCRP, IL-6) both before and after using ARA-290.
If you’re experimenting with the peptide for neuroprotection or recovery from nerve injury, the conservative 2 mg per day approach OR the tapered protocol (i.e. every other day, then weekly) provides a more cautious entry point with clinical precedent.
Do NOT exceed 4 mg daily under the false impression a higher dose will accelerate results.
The trial data explicitly showed no additional benefit to using ARA-290 at 8 mg.
Additionally, this peptide is not meant for indefinite daily use based on the evidence currently available to us.
The longest validated protocol is 15 weeks with a tapered schedule, so keep that in mind.
Cycle ARA-290 accordingly, and combine it with complementary peptides where necessary for a comprehensive neuroprotection strategy.
ARA-290 Dosage: The Bottom Line
ARA-290 represents one of the better-characterized peptides in terms of human dosing data.
We have legitimate Phase II trial evidence supporting once-a-day subcutaneous injections at 4 mg for neuropathic conditions over 28 days, with a clean safety profile in that window.
For anyone dealing with neuropathic pain, small-fiber neuropathy, or nerve damage from inflammatory conditions… this is a compound worthy of your attention.
Stick to clinically validated doses, don’t chase higher doses the data explicitly shows are not superior, and monitor your biomarkers if you choose to experiment beyond published protocols.
Source ARA-290 from BioLongevity Labs or another verified supplier with third-party testing, because purity matters more than anything when you’re injecting a compound designed for nerve tissue.
For more information about this Golden Age agent, see the complete ARA-290 peptide guide and my breakdown of peptides for injury recovery.
Both articles will take you one step closer to being #FullyOptimized.
Isn’t It Time You Became Fully Optimized To Live Longer And Stronger?
Join my #1 online membership group, Fully Optimized Health to receive guidance from me and an elite group of more than 700 male and female biohackers (who all started out just like you)
And don’t forget to check out our other premium educational content dedicated to helping you fully optimize your health:
Quantum Peptides – the A-to-Z system for anyone (newbies & pros alike) desiring to master peptide use for the first time and forever.
Quantum Testosterone – the A-to-Z system for Men & Women to learn to optimize their hormones for explosive energy, lean muscle, and timeless vitality.
The Ultimate GLP-1 Video Masterclass – how to PROPERLY utilize the world’s most powerful weight loss drugs for enhanced fat loss and overall longevity.
The Modern Woman’s Peptide Course – a must-have resource for any woman seeking to become more feminine, sexier, leaner, and healthier through the use of peptides.
Life Enhanced – Unlock the secrets to TOTAL Mind-Body-Spirit Optimization as Hunter Williams and I teach you how to live at the tip of the spear.
30 Days 2 Shredz – Reprogram Your Mind and Body for Maximum Fat Loss in Minimum Time with our Optimized Fasting Protocol
Monica Campbell’s 3 Day PMF Video Training Program – Ignite unbreakable strength, sculpt lean muscle, and conquer workouts fearlessly with my wife Monica’s 3 Day Video training course.
Positive Muscle Failure Video Training Program – Learn how to lift weights correctly for maximum muscle in minimum time while building the physique of your dreams.
See you on the inside!
